FUTURE OF HEALTHCARE

Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products

Endonovo Therapeutics, Inc. | April 26, 2022

Endonovo Therapeutics

Endonovo Therapeutics, Inc. announced an agreement with NAMSA – a leading Global Contract Research Organization and medical device reimbursement specialist – as strategic advisors to develop in-patient and out-patient medical reimbursement strategies for Endonovo’s flagship PEMF product SofPulse®.

“Engaging NAMSA as strategy advisors to develop and apply proven medical device reimbursement strategies is a huge advantage for Endonovo and our shareholders, according to Endonovo CEO Alan Collier. “NAMSA is a proven medical device development partner with relevant therapeutic know-how that is critical when seeking acceleration of reimbursement efforts and commercialization objectives,” he pointed out.

NAMSA was founded in 1967 as a scientific research company and later transitioned into a Global CRO and Medtech (Medical Technologies) reimbursement specialist. Today, it has 1,000 strategic associates who provide Medtech reimbursement advisory expertise to more than 300 clients in 15 global regions.

NAMSA offers a full continuum of reimbursement services for medical technologies. Their reimbursement consultants provide: payer relations, medical policy research, coverage advocacy, Healthcare Common Procedure Coding System  Current Procedural Terminology code analysis/applications and health economic analysis.

Our team strives to bring impactful products like the Endonovo SofPulse into higher adoption. With this technology, and its favorable economics, there are multiple opportunities ahead for serving populations in need. We will work together with the Endonovo team to improve market access for this novel device in the very near term.”,

Joseph Sierra, Director, Reimbursement Consulting, North America, NAMSA

NAMSA provides strategic guidance and tactical support to fast-track medical device commercialization and to make an immediate impact on patient healthcare worldwide. NAMSA’s services have grown to include regulatory, reimbursement and quality consulting as well as clinical research. These additions have helped NAMSA to become the pre-eminent 100% medical device-focused Global CRO that offers proven strategic solutions throughout the full development continuum. NAMSA is the only US FDA ASCA accredited medical device biocompatibility laboratory in the world. This allows medical device sponsors to fast-track commercialization efforts, while achieving time and cost efficiencies in every major market of the world.

Collier stated: “We are fortunate to be working directly with Joseph Sierra, at NAMSA. With over 10 years of reimbursement experience, and his proven track-record in developing successful medical device reimbursement strategies is exemplary and will be helpful in developing the path toward reimbursement for our main product SofPulse®. Joseph is an adjunct instructor at USC Masters of Health Administration Program, and his prior professional work includes successful stints with NeoFect USA and Medtronic Ltd. where he demonstrated a record of success leading roles in reimbursement programs, analysis, and strategies for their medical devices.”

NAMSA’s reimbursement expertise and track-record in the introduction and adoption of medical devices into multiple medical specialties includes: orthopedics, cardiovascular surgery, general surgery, plastic surgery, neurology, robotic surgery and wound care. Collaborating with NAMSA on global reimbursement allows Endonovo to explore reimbursement for the U.S. medical markets as well as the European Union market adoption through SofPulse® medical CE Mark.  Additional target markets would be Taiwan and other Asian countries.

About Endonovo Therapeutics Inc.

Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals® therapeutic devices for pain relief, general wellness and wound curatives. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system disorders, including traumatic brain injury, acute concussions, post-concussion syndrome and multiple sclerosis. The Company's noninvasive Electroceutical® therapeutic device, SofPulse®, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema. It also has CMS national coverage for the treatment of chronic wounds. The Company's current portfolio of preclinical-stage Electroceuticals® therapeutic devices addresses chronic kidney disease, liver disease, non-alcoholic steatohepatitis cardiovascular and peripheral artery disease and ischemic stroke. The Company's noninvasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Spotlight

Every segment in health care is experiencing extraordinary changes in the workforce. Burnout, turnover, rising labor costs and skill gaps are diminishing the supply of qualified workers.

Spotlight

Every segment in health care is experiencing extraordinary changes in the workforce. Burnout, turnover, rising labor costs and skill gaps are diminishing the supply of qualified workers.

Related News

HEALTH TECHNOLOGY, FUTURE OF HEALTHCARE

eSight Introduces New Assistive Device for Legally Blind People

eSight | January 04, 2023

eSight, a leading vision-enhancement platform, announced the launch of eSight Go, its most recent innovation in assistive technology. With its enhanced visual clarity, lightweight design, and expansive field of view, the wearable gadget establishes a new benchmark for enhanced vision technology, allowing people with central vision loss to gain independence in their daily lives. The company said that it has greatly improved the capacity and design of its digital eyewear. It is not only to help people who are blind see better but also to make their lives smoother and more manageable. Through a flexible, wearable design that does not restrict the wearer's peripheral vision, eSight devices improve vision for thousands of people with over 20 eye conditions. In addition, the mobility-preserving structure of eSight Go allows for use anywhere, at any time. eSight Go uses the best-matched camera and lens to project a superior image onto two high-resolution screens for binocular vision. Its users can alter the internal OLED's color and contrast. A broader field of view (45 degrees) amplifies vision for unrivaled mobility. Additionally, its new features include better navigation and image stabilization software, a 12-megapixel camera, 4K capabilities, and full HD OLED panels that deliver the sharpest picture with 170 grams comfortably distributed around the neck. eSight Go will debut at CES 2023 and launch in Q4 2023. The device will be showcased at the Gentex booth (#6341) from January 5-8, 2023. About eSight eSight is an innovative vision platform that promises to help people who are blind see new opportunities. It helps patients with macular degeneration, diabetic retinopathy, and 50 other vision-loss conditions. The first eSight Eyewear prototype was released in 2013. Time Magazine named eSight 3 one of 'The 25 Best Inventions of 2017' while Buzzfeed named it one of the '6 Inventions Changing British Lives in 2017'.

Read More

HEALTHTECH SECURITY, MEDICAL DEVICES

Triad HealthCare Network Harnesses Medication Data to Improve Outcomes for High-Risk Patients

DrFirst | December 14, 2022

Triad HealthCare Network, a provider-led accountable care organization and health technology pioneer DrFirst announced an initiative to improve medication adherence among high-risk patient populations across five counties in North Carolina. Fast access to prescription fill data will empower providers to identify patients with chronic conditions who may not be taking their medications as prescribed and intervene early to alleviate barriers to adherence that can lead to gaps in care, poor outcomes, and hospital readmissions. Every year, medication non-adherence due to factors such as cost, access, coverage status, dosage complexity, or concerns about side effects causes about 125,000 deaths. In addition to needless human suffering, it costs nearly $250 billion to the U.S. healthcare system. Giving providers access to up-to-date prescription fill data can lead to better adherence and shed light on other health-related issues, which creates an opportunity for providers to enhance patient care. "Since patients' medication records are typically fragmented across the care continuum, our clinicians are excited about DrFirst's ability to provide current, comprehensive, and easy-to-access medication history, which will enhance our ability to deliver the right care at the right time. This ability is especially important among patients at high risk of complications, such as those with diabetes or congestive heart failure. In addition, we will be able to further improve care coordination and prevent avoidable admissions and emergency visits due to medication issues." Hanna Park, PharmD, Executive Director of Value-based Performance at Triad HealthCare Network MedHx PRM is based on DrFirst's award-winning MedHx, which streamlines medication reconciliation workflows by providing the most accurate and clinically actionable medication history for individual patients at hospital admission and in the emergency department. For population risk management, MedHx PRM expands prescription fill data to a population of patients to enable risk stratification and easy identification of those who would benefit from early and targeted care interventions. Using clinical analytics, care managers can create panels of high-risk patients or import them from an electronic health record (EHR) system and then easily identify those who are not adhering to medication therapies. In particular, ACOs need access to timely and accurate data to ensure patients get appropriate care while avoiding unnecessary duplication of services and preventing medical errors. "For ACOs to deliver on their promise of coordinated patient care, they need to gather clinical data from multiple systems and structure it in a way that makes it useful for clinicians," said G. Cameron Deemer, president of DrFirst. "Triad HealthCare Network is the first ACO to use MedHx PRM to collect medication data from payers, prescription benefit managers, and EHRs. By pulling thousands of de-duplicated patient medication histories automatically and quickly—usually within hours rather than months—clinicians can meaningfully intervene with patients before they end up back in their local hospital's emergency department."  About Triad HealthCare Network Triad HealthCare Network is a provider-led accountable care organization located in Greensboro, North Carolina. It serves nearly 200,000 people in Alamance, Guilford, Randolph, Rockingham, and part of Forsyth counties. THN is sponsored by Cone Health and is governed and operated by a board of managers and a physician-led operating committee. We believe by working together, our network can provide the right care, at the right place, at the right time. About DrFirst Since 2000, DrFirst has pioneered healthcare technology solutions and consulting services that securely connect people at touchpoints of care to improve patient outcomes. We create unconventional solutions that solve care collaboration, medication management, price transparency, and adherence challenges faced in healthcare. We unite the Healthiverse—the interconnected healthcare universe—by providing our clients with real-time access to the information they need, exactly when and how they need it, so patients get the best care possible. DrFirst solutions are used by nearly 325,000 healthcare professionals, including 220,000 prescribers, 70,000 pharmacies, 300 EHRs and health information systems, and 1,500 hospitals in the U.S. and Canada.

Read More

HEALTH TECHNOLOGY, DIGITAL HEALTHCARE

TytoCare and Baptist Health Collaborate for Virtual Medical Care

Media7 | December 13, 2022

Contents 1. Virtual Medical Service Providers 2. Need For Virtual Care 3. Collaborating For A Better Future Taking medical care to the next level, two prominent U.S. companies recently collaborated to provide virtual care to current and prospective patients worldwide. Baptist Health System, based in Louisville, will reportedly use TytoCare's Home Smart Clinic solution to give its patients a virtual in-depth exam. 1. Virtual Medical Service Providers TytoCare, known for its primary virtual care services, works with prominent healthcare providers to give the best care possible. Dedi Gilad and Ofer Tzadik started TytoCare in 2012. It has been approved by both the FDA and the C.E. This New York-based company works with more than 180 primary health systems, health plans, and strategic partners in the U.S., Europe, Asia, Latin America, and Israel. Baptist Health, on the other hand, is a full-service healthcare system that works to improve the health of the communities it serves. It is the first health system in the U.S. to have all its hospitals recognized by American Nursing Credentialing Center with either a Magnet® or Pathway to Excellence® designation for nursing excellence. 2. Need for Virtual Care The recent phase of the pandemic and the years of lockdown that followed it led to more remote services in all fields, including healthcare. What can be more wonderful than patients getting world-class treatment in any part of the globe with in-depth analysis from the comfort of their homes?! Primary care, emergency care, consultations, and regular check-ups could be provided. TytoCare's Home Smart Clinic solution goes beyond traditional audio and video telehealth services to offer a wider range of options, such as primary, urgent, preventive, chronic, and holistic care. It also provides user engagement services along with AI-powered diagnostic support. As a result, the company resolves almost 90% of visits without an in-person appointment! 3. Collaborating for a Better Future! Coming back to the collaboration part, Baptist Health would be incorporating two effective solutions of TytoCare, namely, TytoHome and TytoClinic. In the former service, patients would need to buy a monitoring device from Baptist Health, enabling a direct source of revenue. With the help of this device, the healthcare providers of Baptist Health would monitor and assist patients with chronic medical conditions. Also, TytoClinic would be an extension of Baptist Health, offering services in workplaces, schools, local clinics, etc. Nevertheless, TytoCare's Home Smart Clinic uses an FDA-approved handheld kit to examine the body's most essential organs. It also measures heart rate and body temperature, thus significantly treating many acute and chronic conditions. Besides, it allows healthcare clinicians to access vital clinical data to monitor, diagnose, and remotely treat patients.

Read More